<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02385851</url>
  </required_header>
  <id_info>
    <org_study_id>CHS-1701-03</org_study_id>
    <nct_id>NCT02385851</nct_id>
  </id_info>
  <brief_title>Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)</brief_title>
  <official_title>A Randomized, Double-Blind, Crossover Study to Compare the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coherus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coherus Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, single-dose, 2-period crossover study in healthy subjects&#xD;
      to assess PK, PD, and safety (including immunogenicity) of a single 6 mg subcutaneous (SC)&#xD;
      injection of CHS-1701 compared with a single 6 mg SC dose of Neulasta®.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, single-dose, 2-period crossover study in healthy subjects&#xD;
      to assess PK, PD, and safety (including immunogenicity) of a single 6 mg subcutaneous (SC)&#xD;
      injection of CHS-1701 compared with a single 6 mg SC dose of Neulasta®.&#xD;
&#xD;
      After screening, eligible subjects will be randomly assigned to 1 of 2 treatment sequences;&#xD;
      CHS-1701 followed by Neulasta® (Sequence A) or Neulasta® followed by CHS-1701, Sequence B).&#xD;
      Treatments will be spaced by a minimum of 6 weeks apart (but no more than 8 weeks). Subjects&#xD;
      will be admitted to the Clinical Pharmacology Unit (CPU) on Day -1 (Period 1) and will be&#xD;
      confined through Hour 96 postdose (a total of approximately 4.5 days and 5 nights). Blood&#xD;
      samples will be collected at specified time points postdose for plasma PK and PD measurements&#xD;
      and the subjects will be closely monitored for safety. Following discharge on the morning of&#xD;
      Day 5 (Period 1) subjects will return to the clinic for additional PK, PD and safety follow&#xD;
      up--daily through Day 9 and at stated interval time points thereafter.&#xD;
&#xD;
      The single dose of the alternate blinded study drug will be given after 6 (but no more than&#xD;
      8) weeks of observation and washout and the above procedures will be repeated (Period 2). A&#xD;
      Follow up Visit will take place 41 (±1) days after the second dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biosimilarity as measured by absolute neutrophil count (ANC)</measure>
    <time_frame>84 Days</time_frame>
    <description>The primary objective of this study is to assess the biosimilarity of CHS-1701 with Neulasta® based on the pharmacokinetics (PK) of pegfilgrastim and the pharmacodynamic (PD) response as measured by absolute neutrophil count (ANC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK Profile: Cmax (tmax), AUC0-t, and t1/2</measure>
    <time_frame>84 Days</time_frame>
    <description>Characterization of the PK profile of CHS-1701 using standard parameters (Cmax (tmax), AUC0-t, and t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Profile as assessed by clinical adverse events (AEs), laboratory variables, vital signs, incidence of antidrug antibodies (ADAs), and local injection site reactions (ISRs).</measure>
    <time_frame>84 Days</time_frame>
    <description>Characterization of the safety profile and tolerance of CHS-1701, as assessed by clinical adverse events (AEs), laboratory variables, vital signs, incidence of antidrug antibodies (ADAs), and local injection site reactions (ISRs).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>CHS-1701/Neulasta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHS-1701 followed by Neulasta (crossover)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neulasta/CHS-1701</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neulasta followed by CHS-1701 (crossover)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHS-1701</intervention_name>
    <arm_group_label>CHS-1701/Neulasta</arm_group_label>
    <arm_group_label>Neulasta/CHS-1701</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <arm_group_label>CHS-1701/Neulasta</arm_group_label>
    <arm_group_label>Neulasta/CHS-1701</arm_group_label>
    <other_name>Neulasta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult male or female of ages 18 to 50 inclusive&#xD;
&#xD;
          2. Body weight &gt; 50 kg (110 lb.) and body mass index between 18 and 32 kg/m2 inclusive&#xD;
&#xD;
          3. Medically healthy with clinically insignificant findings based on medical history,&#xD;
             12-lead ECG, and physical examination&#xD;
&#xD;
          4. Negative urine pregnancy test in women of childbearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous exposure to pegfilgrastim or filgrastim, or known allergy to PEG&#xD;
             (polyethylene glycol)&#xD;
&#xD;
          2. Chemistry and hematology values outside protocol specified range&#xD;
&#xD;
          3. Current or previous cancer, diabetes, or any clinically significant cardiovascular,&#xD;
             metabolic, renal, hepatic, gastrointestinal, hematologic, respiratory, dermatological,&#xD;
             neurological, psychiatric, or other disorder&#xD;
&#xD;
          4. History of chronic or acute respiratory illness within the past 4 weeks&#xD;
&#xD;
          5. Positive urine drug or alcohol screen or unwillingness to abstain from alcohol or&#xD;
             recreational drugs for the duration of study participation&#xD;
&#xD;
          6. No prescription or nonprescription drugs during the study&#xD;
&#xD;
          7. Participation in an investigational clinical study within 30 days prior to screening&#xD;
&#xD;
          8. Known or suspected allergic reaction to latex&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Finck, MD</last_name>
    <role>Study Director</role>
    <affiliation>Coherus Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICON</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <last_update_submitted>August 10, 2015</last_update_submitted>
  <last_update_submitted_qc>August 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

